← Back to patent-cliff list
Oxytocin/Estrogen
Tier C — Watch / tradeOxytocin/Estrogen
Pantarhei Bioscience Bv
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ERs, OT-R
Indications (approved)：股骨头坏死, 脊柱损伤, 肩袖损伤, 膝盖受伤, 椎管狭窄, 男性不育症
Regional status
US
-
EU
-
China
Phase II
2025-06-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Also available in our peptide catalogue
Frequently asked questions
What are the approved indications of Oxytocin/Estrogen?
Approved indications include: 股骨头坏死, 脊柱损伤, 肩袖损伤, 膝盖受伤, 椎管狭窄, 男性不育症.
When does the Oxytocin/Estrogen patent expire?
No public expiry year is available for Oxytocin/Estrogen yet; this page updates once verified.
How do I get a quote for Oxytocin/Estrogen intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30